metyrapone has been researched along with ACTH Syndrome, Ectopic in 30 studies
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.
ACTH Syndrome, Ectopic: Symptom complex due to ACTH production by non-pituitary neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifteen patients with endogenous Cushing's syndrome were treated with metyrapone and/or amino-glutethimide." | 9.05 | Aminoglutethimide and metyrapone in the management of Cushing's syndrome. ( Adamson, U; Sjöberg, HE; Thorén, M, 1985) |
| "We wished to develop optimal criteria for interpreting the single-dose overnight metyrapone test and to compare the diagnostic efficiency of the overnight and the standard 6-dose metyrapone tests for the differential diagnosis of ACTH-dependent Cushing's syndrome." | 7.69 | A comparison of the overnight and the standard metyrapone test for the differential diagnosis of adrenocorticotrophin-dependent Cushing's syndrome. ( Avgerinos, PC; Cutler, GB; Nieman, LK; Oldfield, EH, 1996) |
| "18 patients were studied on 21 occasions: three with Cushing's disease without metyrapone treatment prior to IPSS (M-), 11 with Cushing's disease with metyrapone pretreatment (M+), three with ectopic ACTH syndrome, and one with pseudo-Cushing's syndrome." | 7.69 | Metyrapone pre-treated inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome. ( Atkinson, RL; Cameron, DP; Cuneo, RC; Harper, J; Lee, W; Mitchell, K; Salkield, I; Ward, G, 1997) |
| "To analyse the clinical and biochemical effects of metyrapone in the treatment of Cushing's syndrome." | 7.68 | Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. ( Besser, GM; Grossman, AB; Howlett, TA; Perry, L; Rees, LH; Trainer, PJ; Verhelst, JA; Wass, JA, 1991) |
| "Cushing's syndrome due to bronchial carcinoid tumors that secrete adrenocorticotropin (ACTH) may be difficult to distinguish from pituitary Cushing's disease, since the responses to dexamethasone and metyrapone are sometimes similar." | 7.67 | Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. ( Abboud, C; Carey, RM; Carney, JA; Malchoff, CD; Orth, DN; Pairolero, PC, 1988) |
| "Fifteen patients with endogenous Cushing's syndrome were treated with metyrapone and/or amino-glutethimide." | 5.05 | Aminoglutethimide and metyrapone in the management of Cushing's syndrome. ( Adamson, U; Sjöberg, HE; Thorén, M, 1985) |
| "We wished to develop optimal criteria for interpreting the single-dose overnight metyrapone test and to compare the diagnostic efficiency of the overnight and the standard 6-dose metyrapone tests for the differential diagnosis of ACTH-dependent Cushing's syndrome." | 3.69 | A comparison of the overnight and the standard metyrapone test for the differential diagnosis of adrenocorticotrophin-dependent Cushing's syndrome. ( Avgerinos, PC; Cutler, GB; Nieman, LK; Oldfield, EH, 1996) |
| "18 patients were studied on 21 occasions: three with Cushing's disease without metyrapone treatment prior to IPSS (M-), 11 with Cushing's disease with metyrapone pretreatment (M+), three with ectopic ACTH syndrome, and one with pseudo-Cushing's syndrome." | 3.69 | Metyrapone pre-treated inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome. ( Atkinson, RL; Cameron, DP; Cuneo, RC; Harper, J; Lee, W; Mitchell, K; Salkield, I; Ward, G, 1997) |
| "To analyse the clinical and biochemical effects of metyrapone in the treatment of Cushing's syndrome." | 3.68 | Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. ( Besser, GM; Grossman, AB; Howlett, TA; Perry, L; Rees, LH; Trainer, PJ; Verhelst, JA; Wass, JA, 1991) |
| "Cushing's syndrome due to bronchial carcinoid tumors that secrete adrenocorticotropin (ACTH) may be difficult to distinguish from pituitary Cushing's disease, since the responses to dexamethasone and metyrapone are sometimes similar." | 3.67 | Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. ( Abboud, C; Carey, RM; Carney, JA; Malchoff, CD; Orth, DN; Pairolero, PC, 1988) |
| " Conservative treatment with metyrapone suppressed the Cushing syndrome." | 3.66 | [Successful conservative treatment of bronchial carcinoid with Cushing's syndrome due to ectopic ACTH production]. ( Euler, HH; Herrlinger, JD; Kirmse, L; Kleine, L; Löffler, H; Müller-Hermelink, HK, 1983) |
| "Treatment with metyrapone was started before pituitary surgery." | 2.66 | Pneumocystis pneumonia can complicate medical treatment of hypercortisolism even in outpatients with Cushing's disease. ( Carreau, A; Chabre, O; Cristante, J; Lepelley, M; Mallaret, M, 2020) |
| "ACTH-dependent Cushing's syndrome is a heterogeneous disorder requiring a multidisciplinary and individualized approach to patient management." | 2.44 | Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. ( Bertagna, X; Bertherat, J; Biller, BM; Boscaro, M; Buchfelder, M; Colao, A; Grossman, AB; Hermus, AR; Hofland, LJ; Klibanski, A; Lacroix, A; Lindsay, JR; Melmed, S; Newell-Price, J; Nieman, LK; Petersenn, S; Sonino, N; Stalla, GK; Stewart, PM; Swearingen, B; Vance, ML; Wass, JA, 2008) |
| "We report three cases of long-term treatment of ectopic ACTH syndrome due to metastatic bronchial carcinoid, islet cell carcinoma, and malignant thymoma tumors." | 2.40 | Long-term medical treatment of ectopic ACTH syndrome. ( Comi, RJ; Gorden, P, 1998) |
| "Imaging tests by CT/MRI identified the tumors in 8 of 16 (50%), in 4 of 11 (36%) and 4 of 6 (66." | 1.36 | Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. ( Doi, M; Hirata, Y; Izumiyama, H; Sugiyama, T; Yoshimoto, T, 2010) |
| "Why some bronchial carcinoid tumours are responsive is unknown but it could be because of co-secretion of corticotrophin releasing factor (CRF) and/or expression of glucocorticoid receptors." | 1.29 | Glucocorticoid responsive ACTH secreting bronchial carcinoid tumours contain high concentrations of glucocorticoid receptors. ( Donald, RA; Espiner, EA; Florkowski, CM; Lewis, JG; Wittert, GA, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (30.00) | 18.7374 |
| 1990's | 11 (36.67) | 18.2507 |
| 2000's | 3 (10.00) | 29.6817 |
| 2010's | 5 (16.67) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Saishouji, F | 1 |
| Maeda, S | 1 |
| Hamada, H | 1 |
| Kimura, N | 1 |
| Tamanoi, A | 1 |
| Nishida, S | 1 |
| Sakaguchi, M | 1 |
| Igata, M | 1 |
| Yokoo, K | 1 |
| Kawakami, F | 1 |
| Araki, E | 1 |
| Kondo, T | 1 |
| Cristante, J | 1 |
| Lepelley, M | 1 |
| Mallaret, M | 1 |
| Carreau, A | 1 |
| Chabre, O | 1 |
| Iwayama, H | 1 |
| Hirase, S | 1 |
| Nomura, Y | 1 |
| Ito, T | 1 |
| Morita, H | 1 |
| Otake, K | 1 |
| Okumura, A | 1 |
| Takagi, J | 1 |
| Corcuff, JB | 1 |
| Young, J | 1 |
| Masquefa-Giraud, P | 1 |
| Chanson, P | 1 |
| Baudin, E | 1 |
| Tabarin, A | 1 |
| Oda, N | 1 |
| Miyahara, N | 1 |
| Tabata, M | 1 |
| Minami, D | 1 |
| Ninomiya, K | 1 |
| Kanehiro, A | 1 |
| Komatsubara, M | 1 |
| Inagaki, K | 1 |
| Tanimoto, M | 1 |
| Kiura, K | 1 |
| Doi, M | 1 |
| Sugiyama, T | 1 |
| Izumiyama, H | 1 |
| Yoshimoto, T | 1 |
| Hirata, Y | 1 |
| Aziz, SI | 1 |
| Khattak, MA | 1 |
| Usmani, Z | 1 |
| Ladipeerla, N | 1 |
| Pittman, K | 1 |
| Kawashima, T | 1 |
| Oda, M | 1 |
| Kuno, T | 1 |
| Ueki, H | 1 |
| Yamada, S | 1 |
| Hisatomi, A | 1 |
| Mizoguchi, Y | 1 |
| Kajiume, T | 1 |
| Miyagawa, S | 1 |
| Okada, S | 1 |
| Nishi, Y | 1 |
| Kobayashi, M | 1 |
| Biller, BM | 1 |
| Grossman, AB | 2 |
| Stewart, PM | 1 |
| Melmed, S | 1 |
| Bertagna, X | 1 |
| Bertherat, J | 1 |
| Buchfelder, M | 1 |
| Colao, A | 1 |
| Hermus, AR | 1 |
| Hofland, LJ | 1 |
| Klibanski, A | 1 |
| Lacroix, A | 1 |
| Lindsay, JR | 1 |
| Newell-Price, J | 2 |
| Nieman, LK | 2 |
| Petersenn, S | 1 |
| Sonino, N | 1 |
| Stalla, GK | 1 |
| Swearingen, B | 1 |
| Vance, ML | 1 |
| Wass, JA | 2 |
| Boscaro, M | 1 |
| Hiramatsu, R | 1 |
| Shimada, T | 1 |
| Sato, T | 1 |
| Herrlinger, JD | 1 |
| Euler, HH | 1 |
| Kleine, L | 1 |
| Kirmse, L | 1 |
| Müller-Hermelink, HK | 1 |
| Löffler, H | 1 |
| Wilson, RE | 1 |
| Orth, DN | 2 |
| Nicholson, WE | 1 |
| Mount, CD | 1 |
| Bertagna, XY | 1 |
| Florkowski, CM | 1 |
| Wittert, GA | 1 |
| Lewis, JG | 1 |
| Donald, RA | 1 |
| Espiner, EA | 1 |
| Avgerinos, PC | 1 |
| Oldfield, EH | 1 |
| Cutler, GB | 1 |
| Horiba, N | 1 |
| Suda, T | 1 |
| Tanaka, K | 1 |
| Toriumi, M | 1 |
| Itoh, S | 1 |
| Ogino, Y | 1 |
| Cuneo, RC | 1 |
| Lee, W | 1 |
| Harper, J | 1 |
| Mitchell, K | 1 |
| Ward, G | 1 |
| Atkinson, RL | 1 |
| Salkield, I | 1 |
| Cameron, DP | 1 |
| Trainer, P | 1 |
| Besser, M | 1 |
| Grossman, A | 1 |
| Comi, RJ | 1 |
| Gorden, P | 1 |
| Sanno, N | 1 |
| Tahara, S | 1 |
| Yoshida, Y | 1 |
| Onose, H | 1 |
| Wakabayashi, I | 1 |
| Teramoto, A | 1 |
| Puig, J | 1 |
| Wägner, A | 1 |
| Caballero, A | 1 |
| Rodríguez-Espinosa, J | 1 |
| Webb, SM | 1 |
| Verhelst, JA | 1 |
| Trainer, PJ | 1 |
| Howlett, TA | 1 |
| Perry, L | 1 |
| Rees, LH | 1 |
| Besser, GM | 1 |
| Blunt, SB | 2 |
| Sandler, LM | 1 |
| Burrin, JM | 2 |
| Joplin, GF | 2 |
| Raff, H | 1 |
| Findling, JW | 1 |
| Pirmohamed, M | 1 |
| Chatterjee, VK | 1 |
| Allison, DJ | 1 |
| Malchoff, CD | 1 |
| Abboud, C | 1 |
| Carney, JA | 1 |
| Pairolero, PC | 1 |
| Carey, RM | 1 |
| Cagliero, E | 1 |
| Lorenzi, M | 1 |
| Schteingart, DE | 1 |
| Lloyd, RV | 1 |
| Akil, H | 1 |
| Chandler, WF | 1 |
| Ibarra-Perez, G | 1 |
| Rosen, SG | 1 |
| Ogletree, R | 1 |
| Thorén, M | 1 |
| Adamson, U | 1 |
| Sjöberg, HE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine[NCT02160730] | Phase 2 | 4 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to NIH grant ended.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by ≥50% from baseline at week 4. (NCT02160730)
Timeframe: Baseline, Week 4
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 2 |
A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 0 |
"To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. Normalizing is defined as having urine free cortisol levels within the normal range for that lab value." (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 0 |
The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| R-roscovitine | 2 |
Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | lbs (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 217 | 217.4 |
Mean diastolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 76.5 | 71 |
HbA1c levels are measured at baseline and at study end, these are averaged across all subjects. (NCT02160730)
Timeframe: Baseline, 4 Weeks
| Intervention | Percentage (Mean) | |
|---|---|---|
| Baseline | Study End-4 weeks | |
| R-roscovitine | 6.9 | 7 |
Mean change in systolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 150.3 | 128.3 |
Mean serum cortisol values at baseline and 4 weeks (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| R-roscovitine | 25.6 | 27.1 |
Mean change between baseline and week 4 of fasting blood glucose levels. (NCT02160730)
Timeframe: Baseline, 4 Weeks
| Intervention | g/dL (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 121.4 | 104.3 |
Mean change in Plasma ACTH between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| R-roscovitine | 79.3 | 79.9 |
6 reviews available for metyrapone and ACTH Syndrome, Ectopic
| Article | Year |
|---|---|
Pneumocystis pneumonia can complicate medical treatment of hypercortisolism even in outpatients with Cushing's disease.
Topics: ACTH Syndrome, Ectopic; Adult; Aged; Aged, 80 and over; Cushing Syndrome; Humans; Immunologic Defici | 2020 |
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
Topics: ACTH Syndrome, Ectopic; Adrenal Insufficiency; Adrenalectomy; Adrenocorticotropic Hormone; Cushing S | 2008 |
[Metopiron test].
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Cushing Syndrome; Humans; Hypothalamo-Hypophyse | 1997 |
[Metyrapone test].
Topics: ACTH Syndrome, Ectopic; Adrenal Cortex Diseases; Adrenal Cortex Function Tests; Adrenal Insufficienc | 1997 |
The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Circadian Rhythm; Cor | 1998 |
Long-term medical treatment of ectopic ACTH syndrome.
Topics: ACTH Syndrome, Ectopic; Adolescent; Adrenocortical Hyperfunction; Aminoglutethimide; Antineoplastic | 1998 |
1 trial available for metyrapone and ACTH Syndrome, Ectopic
| Article | Year |
|---|---|
Aminoglutethimide and metyrapone in the management of Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adolescent; Adrenal Gland Neoplasms; Adult; Aminoglutethimide; Clinical Tria | 1985 |
23 other studies available for metyrapone and ACTH Syndrome, Ectopic
| Article | Year |
|---|---|
Ectopic ACTH-producing neuroendocrine tumor occurring with large recurrent metastatic pheochromocytoma: a case report.
Topics: ACTH Syndrome, Ectopic; Adrenal Gland Neoplasms; Adrenocorticotropic Hormone; Aged, 80 and over; Cat | 2022 |
Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: case report and literature review.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Aged; Female; Humans; Hydrocortisone; Lung Neop | 2018 |
Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole.
Topics: ACTH Syndrome, Ectopic; Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Cushing Synd | 2015 |
Pneumocystis Pneumonia Concomitant with Ectopic ACTH Syndrome Caused by a Large Cell Neuroendocrine Carcinoma of the Thymus.
Topics: ACTH Syndrome, Ectopic; Adult; Bronchoalveolar Lavage; Carcinoma, Neuroendocrine; Early Diagnosis; E | 2017 |
Clinical features and management of ectopic ACTH syndrome at a single institute in Japan.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Aged; Corticotropin-Releasing Hormone; D | 2010 |
Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide.
Topics: ACTH Syndrome, Ectopic; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Infusions, Int | 2011 |
Metyrapone for delirium due to Cushing's syndrome induced by occult ectopic adrenocorticotropic hormone secretion.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Cushing Syndrome; Delirium; Enzyme Inhibitors; | 2004 |
Steroid-dependent ACTH-produced thymic carcinoid: regulation of POMC gene expression by cortisol via methylation of its promoter region.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Antimetabolites; Carcinoid Tumor; Child; DNA Me | 2007 |
A case of dexamethasone non-suppressible Cushing's disease hardly differentiated from ectopic ACTH syndrome.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Cushing Syndrome; Dexamethasone; Diagnos | 1983 |
[Successful conservative treatment of bronchial carcinoid with Cushing's syndrome due to ectopic ACTH production].
Topics: ACTH Syndrome, Ectopic; Bronchial Neoplasms; Carcinoid Tumor; Cushing Syndrome; Cyclophosphamide; Do | 1983 |
Human gamma-lipotropin radioimmunoassay: identification of immunoreactive gamma-lipotropin in human plasma and tissue.
Topics: ACTH Syndrome, Ectopic; Addison Disease; Adult; Antibody Specificity; beta-Lipotropin; Female; Human | 1981 |
Glucocorticoid responsive ACTH secreting bronchial carcinoid tumours contain high concentrations of glucocorticoid receptors.
Topics: ACTH Syndrome, Ectopic; Adolescent; Adult; Bronchial Neoplasms; Carcinoid Tumor; Corticotropin-Relea | 1994 |
A comparison of the overnight and the standard metyrapone test for the differential diagnosis of adrenocorticotrophin-dependent Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Cortodoxone; Cushing Syndrome; Humans; Hydrocortisone; Metyrapone; Pilot Pro | 1996 |
Metyrapone pre-treated inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adenoma; Adolescent; Adrenocorticotropic Hormone; Adult; Cortodoxone; Cushin | 1997 |
Ectopic corticotroph adenoma in the cavernous sinus: case report.
Topics: ACTH Syndrome, Ectopic; Cavernous Sinus; Death, Sudden; Dura Mater; Female; Humans; Magnetic Resonan | 1999 |
Cost-effectiveness and accuracy of the tests used in the differential diagnosis of Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adrenal Gland Neoplasms; Adrenal Hyperplasia, Congenital; Adrenocorticotropi | 1999 |
Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adenoma; Adolescent; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; | 1991 |
An evaluation of the distinction of ectopic and pituitary ACTH dependent Cushing's syndrome by clinical features, biochemical tests and radiological findings.
Topics: ACTH Syndrome, Ectopic; Adolescent; Adrenocorticotropic Hormone; Adult; Cushing Syndrome; Dexamethas | 1990 |
A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Corticotropin-Releasing Hormone; Cosyntr | 1989 |
Use of adrenal arterial embolization in severe ACTH-dependent Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adrenal Glands; Carcinoma; Combined Modality Therapy; Cushing Syndrome; Embo | 1989 |
Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Bronchial Neoplasms; Carcinoid Tumor; Co | 1988 |
The corticotropin-releasing factor test in the diagnosis of ectopic ACTH secretion.
Topics: ACTH Syndrome, Ectopic; Adenocarcinoma; Aged; Corticotropin-Releasing Hormone; Cushing Syndrome; Dex | 1987 |
Cushing's syndrome secondary to ectopic corticotropin-releasing hormone-adrenocorticotropin secretion.
Topics: ACTH Syndrome, Ectopic; Bronchial Neoplasms; Carcinoid Tumor; Corticotropin-Releasing Hormone; Cushi | 1986 |